期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 11, 期 7, 页码 1115-1130出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.11.61
关键词
antimitotic agents; BI 2536, BI 6727 (volasertib); GSK461364; GW843682X; HMN-214; NMS-P937 (NMS1286937); novel anticancer drugs; ON 01910.Na; Polo-like kinase (Plk) inhibitors; TAK-960; TKM-080301
类别
资金
- Boehringer Ingelheim
- Novartis
- Roche
Polo-like kinase 1 (Plk1) inhibitors belong to a new class of drugs for the treatment of malignant diseases. They selectively act against a target (Plk1) which is involved in different stages of mitosis such as centrosome maturation, spindle formation, chromosome separation and cytokinesis. Because Plk1 is mainly expressed in proliferating tissues and overexpressed in cancers, its inhibition is potentially less prone to toxicities associated with current antimitotic agents, which also act on nondividing cells. Several Plk1 inhibitors are being evaluated as cancer treatment drugs. Based on the essential role of Plk1 during mitosis, Plk1 inhibitors target all rapidly dividing cells irrespective of their tumor suppressor or oncogene mutations. In this article, their mechanisms of action, efficacy and toxicity profile are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据